DocWire News Editors

DocwireNews

Immunotherapy has become standardized in treating patients with stage IV non-small cell lung cancer (NSCLC), although little is known about the appropriate timing of immunotherapy following ablative therapy. In a study presented at the <a href="https://www.docwirenews.com/category/conference-coverage/asco-2019/">2019 ASCO Annual Meeting,</a> researchers used data from the National Cancer Database (NCDB) to analyze trends in immunotherapy use and its timing related to stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) in stage IV NSCLC patients.NCDB patients included in the analysis were those diagnosed with stage IV NSCLC between 2004 and 2015, treated with SRS or SBRT at any site, and had a minimum of three months follow up. Predictors of immunotherapy use were identified via multivariable logistic regression, and the optimal timepoint between SBRT and immunotherapy correlating with overall survival was found using receiver operator curve analysis. Overall survival was determined through Kaplan-Meier curves, and multivariable Cox regression was employed to identify the predictive factors of survival. By generating a propensity score and integrating it into Kaplan-Meier and cox regressions, the researchers accounted for indication bias.Of the 13,862 patients included in the analysis, 371 had received immunotherapy treatment, and three-quarters had received chemotherapy as well. Those with adenocarcinoma presence, chemotherapy treatment, and more recent year of treatment were more likely to receive immunotherapy. Improved median survival with immunotherapy was shown via univariable Kaplan-meier analysis (17 months vs. 13 months, P&lt;0.0001). Younger age, lower comorbidity score, lower grade, private insurance, and female gender were found to be significant predictors for improved overall survival through multivariable propensity-adjusted cox regression.Regarding immunotherapy treatment after SBRT, patients who received treatment at least 21 days after the start of the radiotherapy were found to <a href="https://www.docwirenews.com/conference-coverage/asco-2019/women-have-longer-overall-survival-than-men-with-non-small-cell-lung-cancer/">survive longer</a> (median survival of 19 months vs. 15 months, P=0.0335).The researchers concluded that the use of immunotherapy in treating stage IV NSCLC after SBRT has increased over time, particularly in patients with adenocarcinoma and those receiving chemotherapy. They also noted that their findings indicate improved outcomes in patients who received immunotherapy at least three weeks after starting SBRT.&nbsp;ReferenceWegner R, Abel S, Hasan S, et al. Time from stereotactic body radiotherapy to immunotherapy as a predictor for outcome in metastatic non small cell lung cancer. Abstract # 9024. Presented at the 2019 ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2019.

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Immunotherapy at Least Three Weeks After SBRT Improves Survival in NSCLC Patients

ASCO 2019

Immunotherapy has become standardized in treating patients with stage IV non-small cell lung cancer (NSCLC), although little is known about the appropriate timing of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe